Corneal stromal injection is an emerging local drug delivery method, characterized by strong targeting, high drug concentration, and prolonged duration of action. It has been preliminarily applied in the treatment of fungal keratitis and neurotrophic corneal diseases. This study aims to investigate the safety and efficacy of anti-VEGF drugs delivered via corneal stromal injection in neovascularization caused by HSK (Herpes Simplex Keratitis). The study has clear medical significance and technical feasibility, and it is expected to promote innovation in the treatment paradigm for corneal neovascularization.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Neovascularization Area
Timeframe: 1、2、4、8、12 week
Corneal Clarity Score
Timeframe: 1、2、4、8、12 week
Best Corrected Visual Acuity (BCVA)
Timeframe: 1、2、4、8、12 week
Conjunctival Hyperemia Score
Timeframe: 1、2、4、8、12 week
Corneal Endothelial Cell Count
Timeframe: 1、2、4、8、12 week